FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | DC | 205/0 |
|--------------|------|-------|
| wasiiiigton, | D.C. | 20549 |

| STATEMENT | OF CHANGES | S IN BENEFICIA | L OWNERSHIP |
|-----------|------------|----------------|--------------------|

| l | OMB APPROVAL | | | | | | | | |
|---------------------|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-02 | | | | | | | | | |
| l | Estimated average burden | | | | | | | | |
| l | hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* Mass Robert D. | | | | 2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [MEIP] | | | | | (Che | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify | | | | | | |
|--|--|------------|---|---|---|--------------|--|--------------------------------------|--------------------|---|---|--|--|---|--|--|
| | I PHARMA | | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 07/02/2020 | | | | | | | X Officer (give title Other (specify below) Chief Medical Officer | | | | |
| 11455 EL CAMINO REAL, SUITE 250 | | | 4 | . If Am | endment, I | Date (| of Original File | ed (Month/D | ay/Year) | | | oint/Group Fili | ing (Check App | licable | | |
| (Street) SAN DIEGO CA 92130 | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | reisuii | | | | | |
| | | | ble I - Non-Do | | | | | _ | - | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Trans Date (Month/ | | е | action 2A. Deemed Execution Date, if any (Month/Day/Year) | | Code (Ins | on Dispos | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 | | | | orm: Direct) or Indirect (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | | | | Code V | Amoun | (A) or (D) | Price | Transacti (Instr. 3 a | on(s) | | (| | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | | | 3A. Deemed Execution Date, if any (Month/Day/Year) | Code | action (Instr. | Derivative E | | Expiration Date o (Month/Day/Year) U | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4) | | | |
| Stock Option (Right to Buy) | \$3.49 | 07/02/2020 | | A | | 230,000 | | (1) | 07/02/2030 | Common Stock | 230,000 | \$0.00 | 230,000 | D | | |
| Stock Option (Right to Buy) | \$1.57 | | | | | | | (2) | 07/28/2025 | Common Stock | 112,500 | | 112,500 | D | | |
| Stock Option (Right to Buy) | \$1.36 | | | | | | | (3) | 07/29/2026 | Common Stock | 135,000 | | 135,000 | D | | |
| Stock Option (Right to Buy) | \$2.83 | | | | | | | (4) | 07/06/2027 | Common Stock | 135,000 | | 135,000 | D | | |
| Stock Option (Right to Buy) | \$4.33 | | | | | | | (5) | 06/22/2028 | Common Stock | 100,000 | | 100,000 | D | | |
| Stock Option (Right to Buy) | \$4.28 | | | | | | | (6) | 07/12/2028 | Common Stock | 130,000 | | 130,000 | D | | |
| Stock Option (Right to Buy) | \$2.52 | | | | | | | (7) | 07/01/2029 | Common Stock | 230,000 | | 230,000 | D | | |

Explanation of Responses:

- 1. One-quarter of such options shall vest on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021.
- 2. All of such options are presently exercisable.
- 3. One-quarter of such options vested on July 29, 2017 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 29, 2017.
- 4. One-quarter of such options vested on July 6, 2018 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 6, 2018. 5. One-quarter of such options vested on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019.
- 6. One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019.
- 7. One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020.

Remarks:

/s/ Brian G. Drazba, as attorney

in fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.